Oxford Nanopore (LSE: ONT) retains 2026 guidance despite weaker first-half trading

Oxford Nanopore Technologies plc (LSE: ONT) expects revenue of approximately £116.5 million for the six months ended 30 June 2026, representing growth of 10% on a reported basis and 12% at constant currency. Trading fell below management expectations as China revenue declined 16%, Middle East disruption reduced regional demand and customer orders in the Americas arrived more slowly than anticipated. Oxford Nanopore retained its headline expectation for 21% to 25% constant-currency revenue growth in 2026, but achieving that range now depends partly on additional collaboration and licensing income during the second half. ONT shares fell as much as 20.5% to 95.61p before recovering to 112.5p, still down 6.5% and leaving investors to question the quality of the maintained guidance.

Why did Oxford Nanopore’s first-half revenue growth fall below management expectations?

Oxford Nanopore’s first-half performance reveals a business growing at materially different speeds across its markets. Europe, the Middle East, Africa and India delivered constant-currency growth of approximately 23%, while revenue from the Americas increased around 12%. Asia Pacific revenue declined 8%, largely because of a substantial contraction in China and the prior-year completion of the PRECISE II contract in Singapore.

China revenue fell approximately 16% as enhanced export controls and changes to Oxford Nanopore’s commercial operations restricted activity. Revenue from the Middle East declined around 14% amid continuing geopolitical disruption. Excluding those two markets, group revenue grew approximately 16% at constant currency, indicating that the sequencing platform’s wider commercial adoption has not stalled.

However, the geographical explanation does not completely remove the execution concern. Oxford Nanopore also experienced slower customer orders and delayed contract wins in the Americas, and management does not expect the entire first-half shortfall to be recovered before the end of the year. The miss therefore reflects a combination of external restrictions, regional instability and internal forecasting risk.

The Americas remain particularly important because they contain a large concentration of academic research institutions, biotechnology companies and potential clinical customers. Growth of 12% would be respectable for many life-sciences companies, but it was below Oxford Nanopore’s expectations and insufficient to offset weakness elsewhere. The result demonstrates how the group’s valuation still requires sustained global growth rather than isolated strength in selected markets.

How much of Oxford Nanopore’s slowdown is structural rather than temporary in 2026?

Some of the first-half weakness has a credible timing explanation. Customer orders can move between reporting periods, large research projects create difficult comparisons and the completion of the PRECISE II contract was disclosed in advance. Secured business expected to ramp during the second half could consequently produce a stronger exit rate.

Other pressures look less temporary. Export controls affecting China are part of a wider geopolitical realignment around advanced technologies, scientific equipment and biological data. Oxford Nanopore may adapt its commercial model, but investors cannot assume that Chinese demand will return quickly to its previous trajectory.

Middle East disruption is similarly difficult to forecast. The underlying demand for genomic surveillance, healthcare research and precision medicine may remain intact, but procurement, logistics and project execution can be delayed when government budgets and institutional priorities shift towards immediate security requirements.

The Americas order shortfall also deserves caution because Oxford Nanopore explicitly said it does not expect full recovery during 2026. When delayed orders are merely postponed, they usually strengthen the following period. When they are not expected to be fully recovered, the risk is that customer budgets, competitive decisions or research funding conditions have changed.

Oxford Nanopore is also moving away from reliance on a small number of major research programmes. This should eventually produce a more diversified revenue base, but the transition creates uneven comparisons. Large contracts provide rapid revenue gains, while replacing them with hundreds of smaller clinical and commercial customers takes longer and requires greater sales and support investment.

Can clinical and biopharma growth compensate for weaker research and regional demand?

Applied Markets delivered the most encouraging part of the update, with revenue increasing approximately 22%. Clinical revenue grew around 35% and BioPharma revenue rose 25%, partly offset by Industrial growth of only 5%. Research revenue increased approximately 5% after several large projects concluded.

The mix change matters because Oxford Nanopore cannot rely indefinitely on academic research spending to support its growth ambitions. Research funding is exposed to government budgets, grant cycles and institutional capital spending. Clinical and pharmaceutical applications have the potential to create more regular utilisation, repeat consumables demand and longer commercial relationships.

Clinical expansion could also make Oxford Nanopore’s technology more embedded in healthcare workflows. Real-time sequencing can support infectious disease surveillance, oncology research and other diagnostic applications, but broader adoption requires regulatory evidence, reproducibility, laboratory integration and reimbursement. Revenue growth is promising, yet converting research technology into routine clinical infrastructure remains a lengthy process.

BioPharma growth offers a nearer-term route to commercial scale. Drug developers increasingly use genomic information in target discovery, biomarker development, clinical trials and manufacturing quality control. Oxford Nanopore can benefit if its technology becomes integrated into repeat pharmaceutical workflows rather than remaining an instrument purchased for individual projects.

PromethION revenue grew approximately 15%, leading growth across Oxford Nanopore’s product categories. Demand for the higher-throughput platform supports the view that customers are using nanopore sequencing for larger and more complex programmes. It also increases the importance of consumables utilisation, since instrument placements create economic value only when customers continue running samples.

The strategic direction is therefore encouraging even though the financial delivery disappointed. Clinical and BioPharma are growing faster than Research, exactly the transition Oxford Nanopore needs. The challenge is that these markets must scale quickly enough to absorb regional weakness and support the company’s path towards profitability.

Why does Oxford Nanopore’s full-year guidance now depend on licensing revenue?

Oxford Nanopore continues to expect constant-currency revenue growth of approximately 21% to 25% for 2026. However, that range includes additional collaboration and licensing revenue opportunities expected during the second half, some of which will be non-recurring.

Excluding those opportunities, management expects constant-currency growth of approximately 16% to 20%. The five-percentage-point gap between the two ranges is significant because it changes the interpretation of the retained guidance. The headline target remains intact, but the expected composition of revenue has become less recurring and more dependent on transactions that must still be recognised.

Collaboration and licensing income can be strategically valuable. It can validate Oxford Nanopore’s intellectual property, expand the technology into new applications and generate revenue without requiring the same level of instrument manufacturing or direct selling. Licensing can also carry attractive margins and accelerate adoption through larger partners.

However, one-time licensing income does not necessarily demonstrate improving customer demand. If Oxford Nanopore reaches its annual growth target primarily through upfront payments, the reported result may look stronger without materially improving the revenue base entering 2027. Investors will therefore need to separate recurring sequencing revenue from contractual income that will not repeat.

The second half must also be substantially stronger than the first. Oxford Nanopore expects support from Applied Markets and the ramp-up of secured business, while maintaining gross-margin guidance of approximately 62%. The August results will need to provide evidence that those contracts are progressing, rather than simply moving the forecasting risk into the final months of the year.

Maintaining the gross-margin target is positive because it suggests the revenue shortfall has not forced Oxford Nanopore into aggressive discounting. It also supports the profitability plan. Nevertheless, a higher margin on non-recurring licensing revenue may make the consolidated percentage look healthier than the economics of the core sequencing business, making revenue disclosure particularly important.

What does the £68.3 million reduction in liquid resources mean for the breakeven plan?

Oxford Nanopore held approximately £234.5 million of cash, cash equivalents and other liquid investments at 30 June, compared with £302.8 million at the end of 2025. The £68.3 million reduction represents a decline of approximately 22.6% in six months.

That movement should not be treated automatically as a recurring operating cash-burn rate. It can include working-capital movements, capital expenditure, inventory investment and other balance-sheet activity that may not repeat evenly. Even so, the reduction increases the importance of Oxford Nanopore meeting its profitability timetable.

Management continues to expect adjusted EBITDA breakeven during 2027 and says progress was made through gross-margin improvement and disciplined cost control. The retained target provides an important financial anchor, but achieving it after weaker first-half trading will require either a sharp revenue acceleration, further spending restraint or both.

Cost control creates its own strategic tension. Oxford Nanopore competes through scientific development, product performance, software, manufacturing capability and commercial support. Cutting expenditure too deeply could protect near-term liquidity while slowing clinical adoption and allowing competing sequencing technologies to advance.

The company’s remaining liquid resources are still substantial and represent around one-fifth of its £1.17 billion market capitalisation. Oxford Nanopore is not facing an immediate balance-sheet crisis. The issue is whether the current resources are sufficient to fund the business through breakeven without another capital raise or a damaging reduction in investment.

The risk increases if licensing income supports reported revenue without generating a comparable improvement in recurring cash flow. Investors will need to examine adjusted EBITDA, operating cash flow, working capital and capital expenditure together when the interim accounts are published. Revenue growth alone will not settle the funding question.

Why did ONT shares reach a new 52-week low despite retained financial guidance?

Oxford Nanopore shares opened at 105.7p and traded as low as 95.61p, a decline of approximately 20.5% from the previous close of 120.3p. The shares subsequently recovered to 112.5p but remained down 6.5%, with approximately 4.67 million shares traded, more than three times the recent daily average.

The intraday low established a new 52-week floor, while the upper end of the annual range remains 224.8p. Even after the partial recovery, ONT is trading at roughly half its 52-week high. The shares have declined about 12.6% over five sessions and approximately 6.9% over one month.

The reaction indicates that investors are looking beyond the unchanged guidance. The market appears to be discounting the increased dependence on collaboration and licensing revenue, the failure to recover all delayed Americas demand and the continued contraction in liquid resources.

Oxford Nanopore is still valued at approximately £1.17 billion, reflecting expectations that its sequencing platform can secure a meaningful position across research, clinical and pharmaceutical markets. That valuation remains difficult to support if recurring growth moves closer to the underlying 16% to 20% range without a corresponding improvement in profitability.

The share-price recovery from the intraday low suggests investors did not interpret the update as a collapse in the company’s commercial case. Clinical and BioPharma growth, retained margin guidance and the FY27 breakeven target provide support. However, the scale of the initial sell-off shows that confidence in management’s forecasting and second-half execution has weakened.

What should investors watch when Oxford Nanopore reports interim results in August?

Oxford Nanopore will publish its interim results on 19 August 2026, when chief executive Francis Van Parys is also expected to provide a strategy update. The presentation will be important because the trading update disclosed revenue and liquidity but did not provide detailed profitability or cash-flow figures.

The first priority will be the adjusted EBITDA loss and evidence supporting management’s statement that progress towards FY27 breakeven continued. Investors will want to determine whether cost discipline reflects lasting operational efficiencies or deferred investment that must return later.

The second priority will be the composition of expected collaboration and licensing revenue. Oxford Nanopore needs to explain which opportunities are secured, how much revenue they may contribute, whether recognition depends on milestones and what proportion could recur beyond 2026.

Regional disclosure will also matter. China may remain structurally difficult, but investors will expect a plan for managing export restrictions and commercial changes. In the Americas, management must explain why delayed orders will not be fully recovered and whether the shortfall reflects funding pressure, competitive losses or longer procurement cycles.

The quality of Applied Markets growth will be another key test. Clinical and BioPharma gains are strategically valuable, but the interim results should show whether growth is broadly distributed across customers and applications. Dependence on a small number of programmes would leave the business vulnerable to the same contract volatility affecting Research.

Finally, cash conversion must become a more visible part of the investment case. A technology platform can create considerable long-term value, but Oxford Nanopore’s immediate credibility depends on reaching breakeven before its financial flexibility becomes constrained. The August update needs to turn a maintained target into a measurable operational bridge.

What are the key takeaways from Oxford Nanopore’s weaker first-half trading update?

• Oxford Nanopore’s 12% constant-currency growth was below expectations despite strong demand outside China and the Middle East.
• China’s 16% revenue decline reflects export-control and commercial pressures that may persist beyond a single reporting period.
• Clinical growth of 35% and BioPharma growth of 25% support the strategic move towards higher-value Applied Markets.
• Research growth of 5% shows why Oxford Nanopore needs a broader commercial revenue base rather than dependence on large scientific projects.
• The retained 21% to 25% annual growth target relies partly on additional collaboration and licensing income, some of which will not recur.
• Underlying constant-currency growth is now expected at 16% to 20%, providing a more cautious measure of core trading momentum.
• Liquid resources declined by £68.3 million during the first half, increasing the importance of achieving adjusted EBITDA breakeven in 2027.
• The 62% gross-margin target remains intact, but investors must determine how much support comes from high-margin licensing revenue.
• ONT’s new 52-week low reflects concern about revenue quality, forecasting reliability and cash consumption rather than an immediate balance-sheet crisis.
• The 19 August interim results must clarify licensing visibility, Americas order delays, regional strategy and the financial route to breakeven.